Welcome to our dedicated page for Orasure Tech news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Tech stock.
OraSure Technologies, Inc. (NASDAQ: OSUR) is a medical devices company focused on point-of-need and home diagnostic tests and sample management solutions. The OraSure news stream on this page highlights company announcements, financial updates, product milestones, governance changes, and shareholder developments that shape the OSUR investment story.
News coverage commonly includes quarterly and year-to-date financial results, where OraSure reports net revenues, gross margins, operating performance, and the mix of diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product revenues. Earnings releases also discuss core business trends, cash and cash equivalents, and share repurchase activity, providing context on the company’s financial condition and capital allocation.
Investors and industry followers can also track product and innovation milestones, such as FDA submissions for the Sherlock rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) and the Colli-Pee at-home urine collection device for sexually transmitted infections. Additional updates may cover launches of research-use products like HEMAcollect PROTEIN, agreements with partners such as GeneDx, and participation in initiatives like the ENDO1000 project.
Governance and corporate developments feature prominently in OraSure news. Recent items include board refreshment, the appointment of new independent directors, changes in board leadership, and the hiring of senior executives such as the Chief Commercial Officer. News also documents shareholder engagement, including communications from Altai Capital Management regarding board nominations and perspectives on company performance and strategy.
By following this OSUR news page, readers can review a chronological record of OraSure’s press releases and related items, covering earnings, product pipeline progress, strategic initiatives, board composition, and shareholder actions, all drawn from official company and partner announcements.
OraSure (NASDAQ: OSUR) said it is progressing a transformation strategy and highlighted regulatory, commercial, operational, and capital-allocation milestones expected in 2026. Key facts include two FDA product submissions for a rapid molecular CT/NG self-test and Colli-Pee, a $40 million share repurchase program, and cost cuts that reduced SG&A by 37% since 2022.
The company said it has cut global staff ~40%, consolidated manufacturing in Pennsylvania, achieved ~260 bps adjusted gross margin expansion, and expects revenue growth in 2026 as product launches scale. OraSure rejected Altai demands to seat its founder and described ongoing proxy-related engagement.
OraSure Technologies (NASDAQ: OSUR) is the target of an activist campaign by Altai Capital Management, which holds about 5% of shares and has nominated two directors, Rishi Bajaj and John Bertrand.
Altai cites chronic underperformance, cash burn on speculative diagnostics, low director ownership, CEO pay misalignment, and urges a strategic review including a potential sale.
OraSure Technologies (NASDAQ: OSUR) reported Q4 2025 revenue of $26.8 million, above midpoint guidance, and total 2025 revenue of $115.0 million (down 38% YoY). GAAP gross margin improved to 41.0%. Q4 GAAP operating loss was $20.1 million and diluted EPS was $(0.27). Cash and cash equivalents were $199.3 million at Dec 31, 2025. The company submitted FDA applications in Dec 2025 for a rapid CT/NG molecular self-test and the Colli-Pee at-home urine collection device and received Health Canada authorization for the OraQuick HIV Self-Test. Q1 2026 revenue guidance: $26–29 million.
OraSure (NASDAQ: OSUR) received a Health Canada license for the OraQuick HIV Self-Test, Canada’s first oral HIV self-test, on Feb 10, 2026. The rapid antibody oral test detects HIV-1 and HIV-2 and delivers results in as little as 20 minutes.
St. Michael’s Hospital (Unity Health Toronto) will serve as exclusive Canadian distributor to provide national access; the test has been available direct-to-consumer in the U.S. since 2012 and is sold in 60+ countries.
OraSure (NASDAQ: OSUR) will report fourth quarter 2025 financial results and host an earnings conference call on February 25, 2026 at 5:00 PM ET. A live webcast will be available via the company's investor relations page and will be archived after the call.
Investors are asked to register and access the webcast at least 10 minutes before the start time.
Altai Capital Management (NASDAQ: OSUR) announced on January 15, 2026 that it has nominated two candidates, John Bertrand and Rishi Bajaj, for election to the OraSure board at the 2026 annual meeting. Altai says it is a beneficial owner of approximately 5.2% of OraSure common stock and cites a December 17 letter outlining concerns about the company’s share price underperformance and management and board capital-allocation decisions. The nominees are presented as bringing healthcare, AI, technology, and investment-management experience to the board. Altai frames the nominations as a push for change to create near- and long-term shareholder value.
OraSure (NASDAQ: OSUR) announced it submitted two separate applications to the U.S. Food and Drug Administration at the end of 2025 for clearance of a rapid molecular CT/NG self-test and the Colli-Pee™ at-home urine collection device for sexually transmitted infections. The CT/NG self-test, built on the Sherlock molecular platform, is designed to deliver results in approximately 30 minutes in an OTC disposable format using a self-collected swab and a handheld reader that requires no electrical connection. OraSure estimates the CT/NG total addressable market at $1.5 billion+. The Colli-Pee™ submission covers multiple STI indications and is pursued with a leading diagnostics platform partner.
OraSure Technologies (NASDAQ: OSUR) confirmed on Dec 17, 2025 that activist investor Altai Capital intends to nominate two director candidates, including founder Rishi Bajaj, for election at the 2026 annual meeting. The company said its Board evaluated Mr. Bajaj and declined to appoint him, has engaged with Altai, and that shareholders are not required to take action now.
OraSure highlighted corporate actions and financials: $216 million cash on hand as of Sept 30, 2025 with no debt, a $40 million share repurchase program, recent Board refresh (seven departures, three additions), and operational steps to improve margins.
Summary not available.
OraSure Technologies (NASDAQ: OSUR) will participate in the Stephens Annual Investment Conference on Wednesday, November 19, 2025. The company’s session includes a Q&A at 10:00 a.m. CT.
A live webcast and replay of the Q&A will be available on the company’s investor relations events page at https://orasure.gcs-web.com/events-and-presentations.